# Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer

Source: https://onco.cc/trials/nct00045968/  
OnCo record `nct00045968` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of DCVax-L in Glioma & glioblastoma and Brain and spinal cord tumours, run by Northwest Biotherapeutics, with a status the registry has not verified recently.

## Summary

Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer is a phase 3 interventional study registered as NCT00045968 by Northwest Biotherapeutics, with 348 participants planned, started 2006-12 and due to reach its primary completion in 2022-11. Interventions recorded: Dendritic cell immunotherapy. Conditions recorded: Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma, Glioma, Brain Cancer, Brain Tumor.

Linked to the drug DCVax-L because the registry names it among its interventions and Glioma & glioblastoma and Brain and spinal cord tumours among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00045968
- Phase: 3
- Setting: A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM)
- Sponsor: Northwest Biotherapeutics
- Enrolled: 348

## Sources

- ClinicalTrials.gov NCT00045968: https://clinicaltrials.gov/study/NCT00045968

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- drugs: [DCVax-L](https://onco.cc/drugs/dcvax-l/)
- companies: [Northwest Biotherapeutics](https://onco.cc/companies/northwest-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct00045968.json